High expression of TRAIL by osteoblastic differentiated dental pulp stem cells affects myeloma cell viability
- Authors:
- Giacomina Brunetti
- Adriana Di Benedetto
- Francesca Posa
- Graziana Colaianni
- Maria Felicia Faienza
- Andrea Ballini
- Silvia Colucci
- Giovanni Passeri
- Lorenzo Lo Muzio
- Maria Grano
- Giorgio Mori
-
Affiliations: Department of Basic Medical Sciences, Neurosciences and Sense Organs, Section of Human Anatomy and Histology, University of Bari Aldo Moro, I‑70121 Bari, Italy, Department of Clinical and Experimental Medicine, University of Foggia, I‑71122 Foggia, Italy, Department of Biomedical Sciences and Human Oncology, Pediatric Section, Neuroscience and Sense Organs, University of Bari Aldo Moro, I‑70121 Bari, Italy, Department of Basic Medical Sciences, Pediatric Section, Neuroscience and Sense Organs, University of Bari Aldo Moro, I‑70121 Bari, Italy, Department of Medicine and Surgery, University of Parma, I‑43121 Parma, Italy, Department of Emergency and Organ Transplantation, Section of Human Anatomy and Histology, University of Bari Aldo Moro, I‑70124, Italy - Published online on: February 15, 2018 https://doi.org/10.3892/or.2018.6272
- Pages: 2031-2039
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
 |
|
Aslan H, Zilberman Y, Kandel L, Liebergall M, Oskouian RJ, Gazit D and Gazit Z: Osteogenic differentiation of noncultured immunoisolated bone marrow-derived CD105+ cells. Stem Cells. 24:1728–1737. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Muraglia A, Cancedda R and Quarto R: Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J Cell Sci. 113:1161–1166. 2000.PubMed/NCBI | |
|
Davies LC, Heldring N, Kadri N and Le Blanc K: Mesenchymal stromal cell secretion of programmed death-1 ligands regulates T cell mediated immunosuppression. Stem Cells. 35:766–776. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Madec AM, Mallone R, Afonso G, Abou Mrad E, Mesnier A, Eljaafari A and Thivolet C: Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia. 52:1391–1399. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, Sussman M, Orchard P, Marx JC, Pyeritz RE and Brenner MK: Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med. 5:309–313. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Scarano A, Crincoli V, Di Benedetto A, Cozzolino V, Lorusso F, Podaliri Vulpiani M, Grano M, Kalemaj Z, Mori G and Grassi FR: Bone regeneration induced by bone porcine block with bone marrow stromal stem cells in a minipig model of mandibular ‘Critical Size’. Stem Cells Int. 2017:90828692017. View Article : Google Scholar : PubMed/NCBI | |
|
Hagenhoff A, Bruns CJ, Zhao Y, von Luttichau I, Niess H, Spitzweg C and Nelson PJ: Harnessing mesenchymal stem cell homing as an anticancer therapy. Expert Opin Biol Ther. 16:1079–1092. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Niess H, von Einem JC, Thomas MN, Michl M, Angele MK, Huss R, Günther C, Nelson PJ, Bruns CJ and Heinemann V: Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): Study protocol of a phase I/II clinical trial. BMC Cancer. 15:2372015. View Article : Google Scholar : PubMed/NCBI | |
|
Nowakowski A, Drela K, Rozycka J, Janowski M and Lukomska B: Engineered mesenchymal stem cells as an anti-cancer trojan horse. Stem Cells Dev. Sep 7–2016.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI | |
|
Yu R, Deedigan L, Albarenque SM, Mohr A and Zwacka RM: Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects. Cell Death Dis. 4:e5032013. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan Z, Kolluri KK, Sage EK, Gowers KH and Janes SM: Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy. Cytotherapy. 17:885–896. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Grisendi G, Spano C, D'Souza N, Rasini V, Veronesi E, Prapa M, Petrachi T, Piccinno S, Rossignoli F, Burns JS, et al: Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas. Stem Cells. 33:859–869. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Marini I, Siegemund M, Hutt M, Kontermann RE and Pfizenmaier K: Antitumor activity of a mesenchymal stem cell line stably secreting a tumor-targeted TNF-related apoptosis-inducing ligand fusion protein. Front Immunol. 8:5362017. View Article : Google Scholar : PubMed/NCBI | |
|
von Karstedt S, Montinaro A and Walczak H: Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nat Rev Cancer. 17:352–366. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, et al: Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol. 28:2839–2846. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Soria JC, Smit E, Khayat D, Besse B, Yang X, Hsu CP, Reese D, Wiezorek J and Blackhall F: Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol. 28:1527–1533. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ganten TM, Koschny R, Sykora J, Schulze-Bergkamen H, Büchler P, Haas TL, Schader MB, Untergasser A, Stremmel W and Walczak H: Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res. 12:2640–2646. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Siegemund M, Seifert O, Zarani M, Džinić T, De Leo V, Göttsch D, Münkel S, Hutt M, Pfizenmaier K and Kontermann RE: An optimized antibody-single-chain TRAIL fusion protein for cancer therapy. MAbs. 8:879–891. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Guiho R, Biteau K, Grisendi G, Taurelle J, Chatelais M, Gantier M, Heymann D, Dominici M and Redini F: TRAIL delivered by mesenchymal stromal/stem cells counteracts tumor development in orthotopic Ewing sarcoma models. Int J Cancer. 139:2802–2811. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Yan C, Song X, Yu W, Wei F, Li H, Lv M, Zhang X and Ren X: Human umbilical cord mesenchymal stem cells delivering sTRAIL home to lung cancer mediated by MCP-1/CCR2 axis and exhibit antitumor effects. Tumour Biol. 37:8425–8435. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lathrop MJ, Sage EK, Macura SL, Brooks EM, Cruz F, Bonenfant NR, Sokocevic D, MacPherson MB, Beuschel SL, Dunaway CW, et al: Antitumor effects of TRAIL-expressing mesenchymal stromal cells in a mouse xenograft model of human mesothelioma. Cancer Gene Ther. 22:44–54. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Compte M, Cuesta AM, Sánchez-Martin D, Alonso-Camino V, Vicario JL, Sanz L and Alvarez-Vallina L: Tumor immunotherapy using gene-modified human mesenchymal stem cells loaded into synthetic extracellular matrix scaffolds. Stem Cells. 27:753–760. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Yang Y, Zhang L, Lu Y, Zhang Q, Fan D, Zhang Y, Zhang Y, Ye Z and Xiong D: Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan. J Hematol Oncol. 10:562017. View Article : Google Scholar : PubMed/NCBI | |
|
Gronthos S, Mankani M, Brahim J, Robey PG and Shi S: Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci USA. 97:pp. 13625–13630. 2000; View Article : Google Scholar : PubMed/NCBI | |
|
Seo BM, Miura M, Gronthos S, Bartold PM, Batouli S, Brahim J, Young M, Robey PG, Wang CY and Shi S: Investigation of multipotent postnatal stem cells from human periodontal ligament. Lancet. 364:149–155. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Sonoyama W, Liu Y, Fang D, Yamaza T, Seo BM, Zhang C, Liu H, Gronthos S, Wang CY, Wang S and Shi S: Mesenchymal stem cell-mediated functional tooth regeneration in swine. PLoS One. 1:e792006. View Article : Google Scholar : PubMed/NCBI | |
|
Pisciotta A, Carnevale G, Meloni S, Riccio M, De Biasi S, Gibellini L, Ferrari A, Bruzzesi G and De Pol A: Human dental pulp stem cells (hDPSCs): Isolation, enrichment and comparative differentiation of two sub-populations. BMC Dev Biol. 15:142015. View Article : Google Scholar : PubMed/NCBI | |
|
Nagatomo K, Komaki M, Sekiya I, Sakaguchi Y, Noguchi K, Oda S, Muneta T and Ishikawa I: Stem cell properties of human periodontal ligament cells. J Periodontal Res. 41:303–310. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Marrelli M, Paduano F and Tatullo M: Human periapical cyst-mesenchymal stem cells differentiate into neuronal cells. J Dent Res. 94:843–852. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Giorgini E, Conti C, Ferraris P, Sabbatini S, Tosi G, Centonze M, Grano M and Moric G: FT-IR microscopic analysis on human dental pulp stem cells. Vibrational Spectroscopy. 57:30–34. 2011. | |
|
Tatullo M, Falisi G, Amantea M, Rastelli C, Paduano F and Marrelli M: Dental pulp stem cells and human periapical cyst mesenchymal stem cells in bone tissue regeneration: Comparison of basal and osteogenic differentiated gene expression of a newly discovered mesenchymal stem cell lineage. J Biol Regul Homeost Agents. 29:713–718. 2015.PubMed/NCBI | |
|
Mori G, Brunetti G, Oranger A, Carbone C, Ballini A, Lo Muzio L, Colucci S, Mori C, Grassi FR and Grano M: Dental pulp stem cells: Osteogenic differentiation and gene expression. Ann N Y Acad Sci. 1237:47–52. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Mori G, Centonze M, Brunetti G, Ballini A, Oranger A, Mori C, Lo Muzio L, Tetè S, Ciccolella F, Colucci S, et al: Osteogenic properties of human dental pulp stem cells. J Biol Regul Homeost Agents. 24:167–175. 2010.PubMed/NCBI | |
|
Mori G, Ballini A, Carbone C, Oranger A, Brunetti G, Di Benedetto A, Rapone B, Cantore S, Di Comite M, Colucci S, et al: Osteogenic differentiation of dental follicle stem cells. Int J Med Sci. 9:480–487. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Di Benedetto A, Carbone C and Mori G: Dental pulp stem cells isolation and osteogenic differentiation: A good promise for tissue engineering. Methods Mol Biol. 1210:117–130. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Di Benedetto A, Brunetti G, Posa F, Ballini A, Grassi FR, Colaianni G, Colucci S, Rossi E, Cavalcanti-Adam EA, Lo Muzio L, et al: Osteogenic differentiation of mesenchymal stem cells from dental bud: Role of integrins and cadherins. Stem Cell Res. 15:618–628. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Posa F, Di Benedetto A, Colaianni G, Cavalcanti-Adam EA, Brunetti G, Porro C, Trotta T, Grano M and Mori G: Vitamin D effects on osteoblastic differentiation of mesenchymal stem cells from dental tissues. Stem Cells Int. 2016:91508192016. View Article : Google Scholar : PubMed/NCBI | |
|
Di Benedetto A, Posa F, Carbone C, Cantore S, Brunetti G, Centonze M, Grano M, Lo Muzio L, Cavalcanti-Adam EA and Mori G: NURR1 downregulation favors osteoblastic differentiation of MSCs. Stem Cells Int. 2017:76170482017. View Article : Google Scholar : PubMed/NCBI | |
|
Tatullo M, Marrelli M, Falisi G, Rastelli C, Palmieri F, Gargari M, Zavan B, Paduano F and Benagiano V: Mechanical influence of tissue culture plates and extracellular matrix on mesenchymal stem cell behavior: A topical review. Int J Immunopathol Pharmacol. 29:3–8. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e452001. View Article : Google Scholar : PubMed/NCBI | |
|
Peter ME, Scaffidi C, Medema JP, Kischkel F and Krammer PH: The death receptors. Results Probl Cell Differ. 23:25–63. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Medema JP, Scaffidi C, Kischkel FC, Shevchenko A, Mann M, Krammer PH and Peter ME: FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 16:2794–2804. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Golks A, Brenner D, Fritsch C, Krammer PH and Lavrik IN: c-FLIPR, a new regulator of death receptor-induced apoptosis. J Biol Chem. 280:14507–14513. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Deveraux QL, Takahashi R, Salvesen GS and Reed JC: X-linked IAP is a direct inhibitor of cell-death proteases. Nature. 388:300–304. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:673–682. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A and Ashkenazi A: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 271:12687–12690. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 104:155–162. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, et al: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 5:157–163. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Tinhofer I, Biedermann R, Krismer M, Crazzolara R and Greil R: A role of TRAIL in killing osteoblasts by myeloma cells. FASEB J. 20:759–761. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Brunetti G, Oranger A, Carbone C, Mori G, Sardone FR, Mori C, Celi M, Faienza MF, Tarantino U, Zallone A, et al: Osteoblasts display different responsiveness to TRAIL-induced apoptosis during their differentiation process. Cell Biochem Biophys. 67:1127–1136. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Roux S, Lambert-Comeau P, Saint-Pierre C, Lépine M, Sawan B and Parent JL: Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis. Biochem Biophys Res Commun. 333:42–50. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Colucci S, Brunetti G, Cantatore FP, Oranger A, Mori G, Pignataro P, Tamma R, Grassi FR, Zallone A and Grano M: The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis. Apoptosis. 12:1623–1632. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Mori G, Brunetti G, Colucci S, Oranger A, Ciccolella F, Sardone F, Pignataro P, Mori C, Karapanou V, Ballini A, et al: Osteoblast apoptosis in periodontal disease: Role of TNF-related apoptosis-inducing ligand. Int J Immunopathol Pharmacol. 22:95–103. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Mori G, Brunetti G, Colucci S, Ciccolella F, Coricciati M, Pignataro P, Oranger A, Ballini A, Farronato D, Mastrangelo F, et al: Alteration of activity and survival of osteoblasts obtained from human periodontitis patients: Role of TRAIL. J Biol Regul Homeost Agents. 21:105–114. 2007.PubMed/NCBI | |
|
Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J and Dixit VM: The receptor for the cytotoxic ligand TRAIL. Science. 276:111–113. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, et al: TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL. EMBO J. 16:5386–5397. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Wu GS, Burns TF, McDonald ER III, Jiang W, Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, et al: KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet. 17:141–143. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Schneider P, Thome M, Burns K, Bodmer JL, Hofmann K, Kataoka T, Holler N and Tschopp J: TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity. 7:831–836. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Yuan J, Gurney A, Goddard AD, Godowski P and Ashkenazi A: A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol. 7:1003–1006. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA and Goodwin RG: The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity. 7:813–820. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Safa AR: c-FLIP, a master anti-apoptotic regulator. Exp Oncol. 34:176–184. 2012.PubMed/NCBI | |
|
Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ and Borden EC: Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 11:915–923. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Lee TJ, Lee JT, Park JW and Kwon TK: Acquired TRAIL resistance in human breast cancer cells are caused by the sustained cFLIP(L) and XIAP protein levels and ERK activation. Biochem Biophys Res Commun. 351:1024–1030. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS and Reed JC: Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J. 18:5242–5251. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Sprick MR, Rieser E, Stahl H, Grosse-Wilde A, Weigand MA and Walczak H: Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J. 21:4520–4530. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Nagata S: Apoptosis by death factor. Cell. 88:355–365. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Ashkenazi A and Dixit VM: Death receptors: Signaling and modulation. Science. 281:1305–1308. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Mueller LP, Luetzkendorf J, Widder M, Nerger K, Caysa H and Mueller T: TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo. Cancer Gene Ther. 18:229–239. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lin T, Huang X, Gu J, Zhang L, Roth JA, Xiong M, Curley SA, Yu Y, Hunt KK and Fang B: Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene. 21:8020–8028. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Krevvata M, Silva BC, Manavalan JS, Galan-Diez M, Kode A, Matthews BG, Park D, Zhang CA, Galili N, Nickolas TL, et al: Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts. Blood. 124:2834–2846. 2014. View Article : Google Scholar : PubMed/NCBI |
